PhaseBio Pharmaceuticals, Inc. (PHAS) financial statements (2021 and earlier)
Company profile
| Business Address |
1 GREAT VALLEY PARKWAY MALVERN, PA 19355 |
| State of Incorp. | DE |
| Fiscal Year End | December 31 |
| SIC | 2834 - Pharmaceutical Preparations (benchmarking) |
| More info | Complete financial analysis Financial benchmarking |
Balance sheet (Statement of financial position) ($ in millions)
| 12/31/2019 Q4 | 9/30/2019 Q3 | 6/30/2019 Q2 | 3/31/2019 Q1 | 12/31/2018 Q4 | 9/30/2018 Q3 | |||
|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||
| Current Assets | ||||||||
| Cash, cash equivalents, and short-term investments | 74 | 82 | 90 | 52 | 61 | 24 | ||
| Cash and cash equivalents | 74 | 82 | 90 | 52 | 61 | 24 | ||
| Restricted cash and investments | 0 | 0 | ||||||
| Receivables | 1 | 1 | 1 | 1 | 0 | 0 | ||
| Other undisclosed current assets | 4 | 1 | 3 | 1 | 1 | 0 | ||
| Total current assets: | 79 | 83 | 95 | 54 | 63 | 25 | ||
| Noncurrent Assets | ||||||||
| Operating lease, right-of-use asset | 2 | 2 | ✕ | ✕ | ||||
| Property, plant and equipment | 2 | 1 | 1 | 0 | 0 | 0 | ||
| Other noncurrent assets | 0 | 0 | 0 | 0 | 0 | 0 | ||
| Other undisclosed noncurrent assets | 2 | 2 | 2 | |||||
| Total noncurrent assets: | 4 | 3 | 3 | 2 | 0 | 3 | ||
| TOTAL ASSETS: | 82 | 86 | 97 | 56 | 63 | 27 | ||
| LIABILITIES AND EQUITY | ||||||||
| Liabilities | ||||||||
| Current Liabilities | ||||||||
| Accounts payable and accrued liabilities | 6 | 4 | 4 | 3 | 5 | 5 | ||
| Accounts payable | 3 | 2 | 3 | 2 | 2 | 2 | ||
| Accrued liabilities | 3 | 1 | 0 | 1 | 3 | 3 | ||
| Employee-related liabilities | 1 | 1 | 0 | |||||
| Interest and dividends payable | 0 | 0 | 0 | |||||
| Debt | 2 | 2 | 1 | 0 | 3 | |||
| Other undisclosed current liabilities | 0 | 0 | ||||||
| Total current liabilities: | 8 | 6 | 6 | 4 | 5 | 8 | ||
| Noncurrent Liabilities | ||||||||
| Long-term debt and lease obligation | 14 | 9 | 8 | 7 | 8 | 4 | ||
| Long-term debt, excluding current maturities | 12 | 8 | 8 | 7 | 8 | 4 | ||
| Operating lease, liability | 2 | 2 | ✕ | ✕ | ||||
| Liabilities, other than long-term debt | 0 | 0 | 0 | 0 | ||||
| Deferred rent credit | 0 | |||||||
| Other liabilities | 0 | 0 | 0 | |||||
| Other undisclosed noncurrent liabilities | 2 | 2 | 6 | |||||
| Total noncurrent liabilities: | 14 | 9 | 10 | 9 | 8 | 10 | ||
| Total liabilities: | 23 | 15 | 16 | 12 | 12 | 18 | ||
| Temporary equity, carrying amount | 126 | |||||||
| Stockholders' equity | ||||||||
| Stockholders' equity attributable to parent | 60 | 71 | 82 | 44 | 51 | (116) | ||
| Common stock | 0 | 0 | 0 | 0 | 0 | 0 | ||
| Treasury stock, value | (0) | (0) | (0) | (0) | (0) | (0) | ||
| Additional paid in capital | 222 | 222 | 221 | 174 | 174 | 2 | ||
| Accumulated deficit | (162) | (151) | (139) | (130) | (123) | (118) | ||
| Other undisclosed stockholders' equity | (0) | |||||||
| Total stockholders' equity: | 60 | 71 | 82 | 44 | 51 | (116) | ||
| TOTAL LIABILITIES AND EQUITY: | 82 | 86 | 97 | 56 | 63 | 27 | ||
Income statement (P&L) ($ in millions)
| 12/31/2019 Q4 | 9/30/2019 Q3 | 6/30/2019 Q2 | 3/31/2019 Q1 | 12/31/2018 Q4 | 9/30/2018 Q3 | ||
|---|---|---|---|---|---|---|---|
| Gross profit: | 1 | 0 | 1 | 1 | 0 | 0 | |
| Operating expenses | (12) | (12) | (10) | (8) | (8) | (5) | |
| Operating loss: | (11) | (12) | (9) | (7) | (8) | (5) | |
| Nonoperating income (expense) (Other Nonoperating Income (Expense)) | (0) | 0 | 0 | 0 | 3 | (3) | |
| Interest and debt expense | (0) | (0) | (0) | (0) | (0) | (1) | |
| Loss before gain (loss) on sale of properties: | (12) | (12) | (9) | (8) | (5) | (9) | |
| Other undisclosed net income | 0 | 0 | 0 | ||||
| Net loss: | (11) | (12) | (9) | (7) | (5) | (9) | |
| Other undisclosed net income attributable to parent | 0 | 0 | 1 | ||||
| Net loss available to common stockholders, diluted: | (11) | (11) | (9) | (7) | (5) | (8) | |
Comprehensive Income ($ in millions)
| 12/31/2019 Q4 | 9/30/2019 Q3 | 6/30/2019 Q2 | 3/31/2019 Q1 | 12/31/2018 Q4 | 9/30/2018 Q3 | ||
|---|---|---|---|---|---|---|---|
| Net loss: | (11) | (12) | (9) | (7) | (5) | (9) | |
| Comprehensive loss, net of tax, attributable to parent: | (11) | (12) | (9) | (7) | (5) | (9) | |
Statements sources
The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.